- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Automatic Translation feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Development of the Japanese Anticholinergic Risk Scale
-
- Mizokami Fumihiro
- Department of Pharmacy, National Center for Geriatrics and Gerontology
-
- Mizuno Tomohiro
- Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine
-
- Taguchi Reina
- Research Department, Institute for Health Economics and Policy, Association for Health Economics Research and Social Insurance and Welfare
-
- Nasu Izumi
- Flatiron Health, Inc.
-
- Arai Sayaka
- Division of Pharmacy, Chiba University Hospital
-
- Higashi Keiichiro
- Department of Pharmacy, Asanogawa General Hospital
-
- Matsumoto Ayaka
- Center for Sarcopenia and Malnutrition Research, Kumamoto Rehabilitation Hospital
-
- Kamei Miwako
- Faculty of Pharmaceutical Sciences, Teikyo Heisei University
-
- Kojima Taro
- Department of Geriatric Medicine, The University of Tokyo
-
- Sakai Takayoshi
- Department of Oral-Facial Disorders, Osaka University Graduate School of Dentistry
-
- Shibata Yuuka
- Department of Pharmaceutical Services, Hiroshima University Hospital
-
- Takeya Yasushi
- Osaka University Graduate School of Medicine Gerontological Nursing Laboratory
-
- Mogi Masaki
- Department of Pharmacology, Ehime University Graduate School of Medicine
-
- Yamada Shizuo
- Center for Pharma-Food Research (CPFR), Graduate School of Pharmaceutical Sciences, University of Shizuoka
-
- Akishita Masahiro
- Tokyo Metropolitan Institute for Geriatrics and Gerontology
Bibliographic Information
- Other Title
-
- 日本版抗コリン薬リスクスケール
Search this article
Description
<p>The Japanese Society of Geriatric Pharmacy established the “Japanese Anticholinergic Risk Scale (JARS) Working Group,” comprising 15 members including physicians, dentists, pharmacists, and primary pharmaceutical researchers. The JARS supports healthcare professionals to evaluate anticholinergic risk accurately.</p><p>A systematic literature review identified 16 relevant articles. The review focused on medications available in Japan and excluded the topical and inhaled medications with localized effects or variable systemic absorption. Scores of JARS were determined by algorithms and expert consensus using the Delphi method. JARS assigns scores to 158 medications used in Japan, categorizing them into three potency groups: 37 drugs scored as 3 (strong), 27 as 2 (moderate), and 94 as 1 (weak).</p><p>JARS is a critical tool for assessing the anticholinergic burden in older Japanese populations. Although primary target of JARS is old adults, young individuals with underlying conditions may also be at increased risk of adverse drug reactions. Therefore, age-specific distinction was not made for JARS which is designed for pharmacists, physicians, dentists, nurses, and other healthcare professionals. The total anticholinergic burden on patients is calculated by summing each scores of individual medications, reflecting the risk posed by the cumulative anticholinergic effects.</p>
Journal
-
- Journal of Geriatric Pharmacy
-
Journal of Geriatric Pharmacy 7 (S1), S1-S26, 2024-09-10
Japanese Society of Geriatric Pharmacy
- Tweet
Details 詳細情報について
-
- CRID
- 1390583469490436352
-
- ISSN
- 24334065
-
- Text Lang
- en
-
- Data Source
-
- JaLC
-
- Abstract License Flag
- Disallowed